No Detail Found!

Clinical and Autoantibody Profile of Systemic Sclerosis Patients in Saudi Arabia: A Single-Center Retrospective Study

Author(s)
Hussam A. Alsulmi Department of Medicine, College of Medicine, Qassim University, Qassim, Saudi Arabia
Abstract
Objectives: Background: Systemic Sclerosis (SSc) is a rare autoimmune disease with significant ethnic and geographic variability. Autoantibody patterns and organ involvement influence prognosis. Data on SSc from Saudi Arabia are scarce. To describe the clinical presentation, autoantibody profile and organ involvement of Saudi SSc patients and to explore associations between autoantibodies and Interstitial Lung Disease (ILD). Methods: We conducted a retrospective observational study at a single tertiary hospital in Saudi Arabia. Adult patients fulfilling the 2013 ACR/EULAR classification criteria for SSc between 2015-2024 were included. Demographic, clinical and serologic data were extracted from medical records. Associations between SSc subtypes, antibody profiles and ILD were analyzed. Results: Twenty-one patients were included (95.2% female; mean age 50.0±13.4 years; mean age at disease onset 33.7±10.4 years). Diffuse cutaneous SSc (dcSSc) accounted for 76.2% and limited cutaneous SSc (lcSSc) for 23.8%. Common manifestations included gastroesophageal reflux disease (95.2%), Raynaud's phenomenon (90.5%), sclerodactyly (90.5%) and ILD (76.2%). Autoantibodies were frequent: ANA (95.2%), anti-topoisomerase I (ATA, 57.1%) and Anti-Centromere (ACA, 10%). ILD was strongly associated with dcSSc (100% vs. 0% in lcSSc, p<0.001) and trended toward association with ATA positivity (91.7% vs. 8.3%, p = 0.055). All ACA-positive patients (n = 2) were ILD-negative. Conclusion: This first Saudi cohort demonstrates a younger age at diagnosis and a high prevalence of ILD compared to international reports. ATA was associated with ILD, while ACA appeared absent among ILD cases. Given the very small sample size, these findings should be considered hypothesis-generating and warrant confirmation in larger, multicenter studies.
Publication Details
Page(s) 223-230
Published Journal: Journal of Pioneering Medical Sciences, Volume: 14, Issue: S2, Year: 2025

Request the full text from PASTIC

Keywords
Systemic sclerosis, scleroderma, Anti-centromere antibody, Interstitial lung disease, Anti-Topoisomerase I
References
Otair Al,H. Al . .Pulmonary Arterial Hypertension in Saudi Patients with Systemic Sclerosis: Clinical and Hemodynamic Characteristics and Mortality. ” Annals of Thoracic Medicine, 14(2019) : 83.
Åkesson A.,Wollheim F.A. . .Organ Manifestations in 100 Patients with Progressive Systemic Sclerosis: A Comparison between the CREST Syndrome and Diffuse Scleroderma. ” Rheumatology, 28(1989) : 281-286.
Ioannidis J.P.A. .2004 .Mortality in Systemic Sclerosis: An International Meta-Analysis of Individual Patient Data. American Journal of Medicine, 04(1) : 2-10.
Al-Dhaher F.F. .2008 .Determinants of Morbidity and Mortality of Systemic Sclerosis in Canada.” Seminars in Arthritis and Rheumatism. , 06(4) : 269-277.
Hashimoto A.,April 2012 . .. Clinical Features of 405 Japanese Patients with Systemic Sclerosis.” Modern Rheumatology, 22(2) : 272-279.
Van Den Hoogen .2013 .“2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League against Rheumatism Collaborative Initiative.” Annals of the Rheumatic Diseases. , 72(11) : 1747-1755.
LeRoy E.C. . .Scleroderma (Systemic Sclerosis): Classification, Subsets and Pathogenesis. ” Journal of Rheumatology, 15(1988) : 202-205.
Rose S. . .. Gastrointestinal Manifestations of Scleroderma.” Gastroenterology Clinics of North America, 8553(05) : 70021-2.
Al-Dhaher F.F. .2008 .Determinants of Morbidity and Mortality of Systemic Sclerosis in Canada.” Seminars in Arthritis and Rheumatism. , 06(4) : 269-277.
Steen V.D.,April 2005 . .Kidney Disease Other than Renal Crisis in Patients with Diffuse Scleroderma. ” Journal of Rheumatology, 32(4) : 649-655.
Levey A.S. . .Definition and Classification of Chronic Kidney Disease: A Position Statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 67(2005) : 2089-2100.
Hatano S.T.,Strasser S.T. .1975 .. Primary Pulmonary Hypertension: Report on a WHO Meeting, : .
Schachna L. .2098 .. Age and Risk of Pulmonary Arterial Hypertension in Scleroderma.” Chest, 10(6) : 2098-2104.
Tan E.M. .1982 .The 1982 Revised Criteria for the Classification of Systemic Lupus Erythematosus. Arthritis & Rheumatism, 25(11) : 1271-1277.
Arnett F.C. . .The American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis. Arthritis & Rheumatism, 31(1988) : 315-324.
Barnett A.J. . .A Survival Study of Patients with Scleroderma Diagnosed over 30 Years (1953-1983): The Value of a Simple Cutaneous Classification in the Early Stages of the Disease. ” Journal of Rheumatology, 15(1988) : 276-283.
Alam F. .2019 .Characteristics of Patients with Systemic Sclerosis Living in Qatar. Qatar Medical Journal, (2019) : 16.
Sujau I. .2015 .Clinical and Autoantibody Profile in Systemic Sclerosis: Baseline Characteristics from a West Malaysian Cohort. International Journal of Rheumatic Diseases, 18(4) : 459-465.
Simeón-Aznar C.P. . .Registry of the Spanish Network for Systemic Sclerosis: Clinical Pattern According to Cutaneous Subsets and Immunological Status.” Seminars in Arthritis and Rheumatism. , 41(6) : 789-800.
Wielosz E. . .Comparison of Clinical and Serological Parameters in Female and Male Patients with Systemic Sclerosis. ” Reumatologia, 53(2015) : 315-320.
Hashimoto A.,April 2012 . .. Clinical Features of 405 Japanese Patients with Systemic Sclerosis.” Modern Rheumatology, 22(2) : 272-279.
Sujau I. .2015 .Clinical and Autoantibody Profile in Systemic Sclerosis: Baseline Characteristics from a West Malaysian Cohort. International Journal of Rheumatic Diseases, 18(4) : 459-465.
Al-Sheikh H. .2019 .Ethnic Variations in Systemic Sclerosis Disease Manifestations, Internal Organ Involvement and Mortality. ” Journal of Rheumatology, March, : .
0

Citations

0

Downloads

46

Views